New drug cocktail may spare hodgkin patients from stem cell transplant
NCT ID NCT04561206
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether combining two drugs—brentuximab vedotin and nivolumab—can effectively treat classical Hodgkin lymphoma that has relapsed or not responded to initial treatment. The goal is to achieve a complete response without needing a stem cell transplant. About 31 participants will receive the drug combination intravenously, and researchers will track how long they remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin and nivolumab
- What this could lead to
- If successful, this drug combination could offer an effective treatment for Hodgkin lymphoma that has returned or not responded to initial therapy, potentially avoiding the need for a stem cell transplant.
- What could go wrong
- This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the treatment may not work as well as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hackensack University Medical Center/John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Chicago Cancer Research Center
RECRUITINGChicago, Illinois, 60637, United States